Skip to main content

Table 2 Overview of published MAIC in SpA*

From: The need for comparative data in spondyloarthritis

Year Patient-level data Published data Sponsor Type of publication
Treatment A (trial name; ClinicalTrials.gov identifier) Treatment B (trial name; ClinicalTrials.gov identifier)
Ankylosing spondylitis
 2016 Secukinumab (MEASURE 2; NCT01649375) Adalimumab (ATLAS; NCT00195819) Novartis Abstract [5]
 2016 Adalimumab (ATLAS; NCT00195819) Secukinumab (pooled MEASURE 1 [NCT01358175], MEASURE 2 [NCT01649375]) Abbvie Abstract [6]
 2016 Secukinumab (MEASURE 2; NCT01649375) Adalimumab (ATLAS; NCT00195819) Novartis Abstract [7]
 2016 Secukinumab (MEASURE 1; NCT01358175) Adalimumab (ATLAS; NCT00195819) Novartis Abstract [8]
 2016 Secukinumab (pooled MEASURE 1 [NCT01358175], MEASURE 2 [NCT01649375]) Adalimumab (ATLAS; NCT00195819) Novartis Abstract [9]
 2017 Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) Golimumab (GO-RAISE; NCT00265083) Novartis Abstract [10]
 2017 Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) Golimumab (GO-RAISE; NCT00265083) Novartis Abstract [11]
 2017a Secukinumab (MEASURE 2; NCT01649375) Adalimumab (ATLAS; NCT00195819) Novartis Abstract [12]
Psoriatic arthritis
 2013 Adalimumab (ADEPT; NCT00195689) Etanercept (Mease et al. 2004), infliximab (IMPACT 2; NCT00051623) Abbvie Manuscript [13]
 2015 Adalimumab (ADEPT; NCT00195689) Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) Abbvie Abstract [14]
 2016 Secukinumab (FUTURE 2; NCT01752634) Adalimumab (ADEPT; NCT00195689) Novartis Abstract [15]
 2016 Secukinumab (FUTURE 2; NCT01752634) Adalimumab (ADEPT; NCT00195689) Novartis Abstract [16]
 2016 Secukinumab (FUTURE 2; NCT01752634) Etanercept (Mease et al. 2004) Novartis Abstract [17]
 2016 Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) Adalimumab (ADEPT; NCT00195689) Novartis Abstract [18]
 2016 Secukinumab (FUTURE 2; NCT01752634) Infliximab (IMPACT 2; NCT00051623) Novartis Abstract [19]
 2016a Secukinumab (FUTURE 2; NCT01752634) Adalimumab (ADEPT; NCT00195689) Novartis Abstract [20]
 2017 Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) Interferon (IMPACT 2; NCT00051623) Novartis Abstract [21]
 2017a Secukinumab (FUTURE 2; NCT01752634) Infliximab (IMPACT 2; NCT00051623) Novartis Abstract [22]
 2017a Secukinumab (FUTURE 2; NCT01752634) Etanercept (Mease et al. 2004) Novartis Abstract [23]
 2017a Secukinumab (FUTURE 2; NCT01752634) Adalimumab (ADEPT; NCT00195689) Novartis Abstract [24]
 2017 Adalimumab (ADEPT; NCT00195689) Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) Abbvie Manuscript [25]
  1. *Up to December 2017
  2. aCost per responder analysis
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us